SCHEMBL25178742

SCHEMBL25178742

COC(=O)N(C1c2ccccc2-c2ccccc21)[C@@H](Cc1ccccc1Cl)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.39
▸ PPARA Q07869 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ HPGD P15428 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.35
▸ ITGB1 P05556 1/20 0.35
▸ ITGA4 P13612 1/20 0.35
▸ ITGB7 P26010 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ FABP5 Q01469 3/20 0.34
▸ FABP4 P15090 2/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ FABP7 O15540 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ C5AR1 P21730 1/20 0.34
▸ PDE3B Q13370 1/20 0.33
▸ PDE3A Q14432 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30510321 1.00 PPARG (0.39) PPARGPPARAALDH1A1HPGDNPSR1
SCHEMBL25179602 0.90 ALDH1A1 (0.33) PPARGPPARAALDH1A1HPGDNPSR1
SCHEMBL30510415 0.90 ALDH1A1 (0.33) PPARGPPARAALDH1A1HPGDNPSR1
SCHEMBL30510351 0.87 MAPT (0.35) ALDH1A1HPGDLMNAKMT2AMAPT
SCHEMBL30767804 0.87 PPARG (0.39) PPARGPPARAALDH1A1HPGDITGB1
SCHEMBL25179578 0.87 PPARG (0.39) PPARGPPARAALDH1A1HPGDITGB1
SCHEMBL25186515 0.86 PPIA (0.41) PPARGPPARAALDH1A1ITGB1ITGA4
SCHEMBL27215385 0.86 PPIA (0.41) PPARGPPARAALDH1A1ITGB1ITGA4
SCHEMBL25185995 0.86 ALDH1A1 (0.40) PPARGPPARAALDH1A1HPGDITGB1
SCHEMBL4600067 0.84 CTRB1 (0.40) PPARGPPARAALDH1A1ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 — — US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 — — EP disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS PPARG 4292/4885PPARA 3880/4885ALDH1A1 4838/4885
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND VIP, IAPP, KRAS PPARG 3626/4885PPARA 3079/4885ALDH1A1 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback